Torsten O Nielsen

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. pmc Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
    J Natl Cancer Inst 101:736-50. 2009
  2. pmc Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor
    Hongwei Cheng
    Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada V5Z 1M9
    Sarcoma 2010:174528. 2010
  3. pmc Kaposi sarcoma of the adrenal gland resembling epithelioid angiosarcoma: a case report
    Hassan Huwait
    Anatomical Pathology JP1401, Vancouver Hospital, 855 West 12th Avenue, Vancouver, BC, V5Z 1M9, Canada
    Sarcoma 2011:898257. 2011
  4. pmc Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma
    Anne Nguyen
    Jack Bell Research Centre, Vancouver Coastal Health Research Institute, The University of British Columbia, 553 2660 Oak Street, Vancouver, BC, Canada V6H3Z6
    Sarcoma 2009:794901. 2009
  5. pmc Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer
    Martin Buess
    Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
    Genome Biol 8:R191. 2007
  6. pmc Are triple-negative tumours and basal-like breast cancer synonymous?
    Emad A Rakha
    Breast Cancer Res 9:404; author reply 405. 2007
  7. pmc Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
  8. pmc Small blue round cell tumor of the interosseous membrane bearing a t(2;22)(q34;q12)/EWS-CREB1 translocation: a case report
    Marina Pacheco
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
    Mol Cytogenet 3:12. 2010
  9. ncbi request reprint Microarray analysis of sarcomas
    Torsten O Nielsen
    British Columbia Cancer Agency, Vancouver Coastal Health Research Institute, and Department of Pathology, University of British Columbia, Canada
    Adv Anat Pathol 13:166-73. 2006
  10. ncbi request reprint Translating gene expression into clinical care: sarcomas as a paradigm
    Torsten O Nielsen
    Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 28:1796-805. 2010

Detail Information

Publications77

  1. pmc Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
    J Natl Cancer Inst 101:736-50. 2009
    ....
  2. pmc Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor
    Hongwei Cheng
    Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada V5Z 1M9
    Sarcoma 2010:174528. 2010
    ..The results from this model support clinical trials of equivalent humanized agents and anti-CSF1R small molecule drugs in cases of tenosynovial giant cell tumor refractory to conventional local therapy...
  3. pmc Kaposi sarcoma of the adrenal gland resembling epithelioid angiosarcoma: a case report
    Hassan Huwait
    Anatomical Pathology JP1401, Vancouver Hospital, 855 West 12th Avenue, Vancouver, BC, V5Z 1M9, Canada
    Sarcoma 2011:898257. 2011
    ..Immunohistochemistry for human herpes virus-8 was strongly positive in the tumor cells. To the best of our knowledge, this is the first report of an anaplastic Kaposi sarcoma in the adrenal gland...
  4. pmc Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma
    Anne Nguyen
    Jack Bell Research Centre, Vancouver Coastal Health Research Institute, The University of British Columbia, 553 2660 Oak Street, Vancouver, BC, Canada V6H3Z6
    Sarcoma 2009:794901. 2009
    ..Additionally, we find that the NF-kappaB inhibitor BAY 11-7085 synergizes with MS-275. We conclude that agents inhibiting NF-kappaB synergize with HDAC inhibitors against synovial sarcoma...
  5. pmc Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer
    Martin Buess
    Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
    Genome Biol 8:R191. 2007
    ..Perturbations in cell-cell interactions are a key feature of cancer. However, little is known about the systematic effects of cell-cell interaction on global gene expression in cancer...
  6. pmc Are triple-negative tumours and basal-like breast cancer synonymous?
    Emad A Rakha
    Breast Cancer Res 9:404; author reply 405. 2007
  7. pmc Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
    ..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested...
  8. pmc Small blue round cell tumor of the interosseous membrane bearing a t(2;22)(q34;q12)/EWS-CREB1 translocation: a case report
    Marina Pacheco
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
    Mol Cytogenet 3:12. 2010
    ..The group of small blue round cell tumors encompasses a heterogeneous group of neoplasms characterized by primitive appearing round cells with few distinguishing histologic features...
  9. ncbi request reprint Microarray analysis of sarcomas
    Torsten O Nielsen
    British Columbia Cancer Agency, Vancouver Coastal Health Research Institute, and Department of Pathology, University of British Columbia, Canada
    Adv Anat Pathol 13:166-73. 2006
    ..Nevertheless, results need to be interpreted in the context of histopathology and validated by complementary technologies and/or other research groups...
  10. ncbi request reprint Translating gene expression into clinical care: sarcomas as a paradigm
    Torsten O Nielsen
    Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 28:1796-805. 2010
    ..Despite challenges in organization and accrual, future clinical trials of sarcomas need to be designed that take into account specific molecular subtypes as distinct diseases...
  11. pmc A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 16:5222-32. 2010
    ....
  12. ncbi request reprint Discovery research to clinical trial: a ten year journey
    Torsten O Nielsen
    Anatomical Pathology, Vancouver Hospital and Health Sciences Ctr, 855 West 12th Avenue, Vancouver, British Columbia
    Clin Invest Med 33:E342-8. 2010
    ..Results from exciting, emerging next generation sequencing technologies will need to undergo similar validation and preclinical studies before they can be expected to impact patient care...
  13. ncbi request reprint Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers
    Stephen Chia
    Division of Medical Oncology, Breast Cancer Outcomes Unit, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 26:5697-704. 2008
    ..This study assessed the prognostic impact of HER2 overexpression/amplification in a large series of node-negative breast cancers...
  14. pmc Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes
    Golareh Habibi
    Laboratory for Oncogenomic Research, Departments of Pediatrics and Experimental Medicine, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
    Breast Cancer Res 10:R86. 2008
    ..We therefore investigated whether YB-1 identifies patients at risk for either reduced relapse free survival or decreased r breast cancer specific survival (BCSS) across all tumor subtypes by evaluating 4,049 cases...
  15. ncbi request reprint Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:1368-76. 2008
    ..This study directly compares the prognostic significance between three- and five-biomarker surrogate panels to define intrinsic breast cancer subtypes, using a large clinically annotated series of breast tumors...
  16. ncbi request reprint MDM2 protein expression is a negative prognostic marker in breast carcinoma
    Dmitry A Turbin
    Genetic Pathology Evaluation Centre of the Department of Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada
    Mod Pathol 19:69-74. 2006
    ..Immunohistochemical studies of MDM2 in more than 2000 breast carcinomas show that MDM2 is an independent negative prognostic marker...
  17. ncbi request reprint Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models
    Shuzhen Liu
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Mol Cancer Ther 7:1751-61. 2008
    ..Histone deacetylase inhibitors show promising preclinical activity in multiple clear cell sarcoma models...
  18. doi request reprint Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients
    Shuzhen Liu
    Genetic Pathology Evaluation Centre at Vancouver General Hospital, Prostate Center, University of British Columbia, Vancouver, BC, Canada
    Breast Cancer Res Treat 119:53-61. 2010
    ..PR adds significant prognostic value in breast cancer beyond that obtained with estrogen receptor alone...
  19. ncbi request reprint Breast cancer subtypes and the risk of local and regional relapse
    K David Voduc
    Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    J Clin Oncol 28:1684-91. 2010
    ..Subtype assignment was accomplished using a validated six-marker immunohistochemical panel applied to tissue microarrays...
  20. doi request reprint Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma
    Amanda Jagdis
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
    Am J Surg Pathol 33:1743-51. 2009
    ....
  21. pmc Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy
    Anna L Stratford
    Laboratory for Oncogenomic Research, Department of Pediatrics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada
    Breast Cancer Res 9:R61. 2007
    ..We pursued this in light of our recent work showing that YB-1 induces the expression of EGFR, a new BLBC marker...
  22. ncbi request reprint Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre at Vancouver General Hospital, Prostate Centre, and University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 24:5637-44. 2006
    ....
  23. ncbi request reprint Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival
    Sam M Wiseman
    Genetic Pathology Evaluation Center at the Prostate Research Center of Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer 103:1770-7. 2005
    ..The objective of the current study was to determine the frequency and the possible prognostic effect of coexpression of HER-1, HER-2, HER-3, and HER-4 by breast carcinoma...
  24. ncbi request reprint NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis
    Leah M Prentice
    Department of Pathology and Prostate Centre, Genetic Pathology Evaluation Centre, Vancouver General Hospital, Vancouver, BC, Canada V6H 3Z6
    Oncogene 24:7281-9. 2005
    ..Of the two genes in the novel amplicon, expression of SPFH2 correlated most significantly with amplification. This amplicon may emerge as a result of breakpoints and chromosomal rearrangements within the NRG1 locus...
  25. ncbi request reprint The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype
    David Voduc
    Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    Hum Pathol 39:1431-7. 2008
    ..In conclusion, the combination of high cyclin E and Skp2 expression predicts for poor prognosis in breast cancer in univariate analysis only, it is associated with high risk features, and it is associated with the basal phenotype...
  26. doi request reprint Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer
    Simon J Crabb
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Breast Cancer 8:249-56. 2008
    ..We hypothesized that molecular classification based on breast cancer biology would predict the presence of nodal involvement at diagnosis, which might aid treatment decisions regarding the axilla...
  27. ncbi request reprint Fluorescence in situ hybridization for the detection of t(X;18)(p11.2;q11.2) in a synovial sarcoma tissue microarray using a breakapart-style probe
    Jefferson Terry
    Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Diagn Mol Pathol 14:77-82. 2005
    ..The CISH probes produced signals too weak to interpret. The use of breakapart FISH probes is a relatively quick procedure for detection of synovial sarcoma translocations and can be applied to archival specimens in tissue microarrays...
  28. ncbi request reprint Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
    ..Currently, there exist clinical assays that identify ER+/luminal and HER2-overexpressing tumors, and we sought to develop a clinical assay for breast basal-like tumors...
  29. doi request reprint Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma
    Joanna M Lubieniecka
    The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada
    Cancer Res 68:4303-10. 2008
    ..Furthermore, our work highlights a possible mechanism behind the efficacy of a clinically applicable HDAC inhibitor in synovial sarcoma treatment...
  30. ncbi request reprint Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases
    Dmitry A Turbin
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada
    Breast Cancer Res Treat 110:417-26. 2008
    ..Our study compares visual scoring of ER in invasive breast cancer by histopathologists to quantitation of staining using a fully automated system...
  31. pmc Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics
    Le Su
    Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
    Cancer Cell 21:333-47. 2012
    ..Together, these studies define a fundamental role for aberrant ATF2 transcriptional dysregulation in the etiology of synovial sarcoma...
  32. ncbi request reprint Gene expression profiling of breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, Vancouver, British Columbia V6H 3Z6, Canada
    Annu Rev Pathol 3:67-97. 2008
    ..Prospective trials are now underway to determine the value of such tools for clinical decision making in breast cancer; these efforts may serve as a model for using such approaches in other tumor types...
  33. doi request reprint Metastatic behavior of breast cancer subtypes
    Hagen Kennecke
    Vancouver Clinic, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 28:3271-7. 2010
    ..Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected...
  34. ncbi request reprint Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models
    Jefferson Terry
    Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 11:5631-8. 2005
    ....
  35. pmc Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV
    Tony L Ng
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, Canada, V5Z 4E6
    J Mol Diagn 9:459-63. 2007
    ....
  36. ncbi request reprint A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard
    Jennifer R Won
    1 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada 2 Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Mod Pathol 26:1438-50. 2013
    ....
  37. ncbi request reprint TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies
    Jefferson Terry
    Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Am J Surg Pathol 31:240-6. 2007
    ..Our findings establish TLE as a robust immunohistochemical marker for synovial sarcoma, and may have implications for understanding the biology of synovial sarcoma and for developing experimental therapies for this cancer...
  38. doi request reprint YWHAE-FAM22 endometrial stromal sarcoma: diagnosis by reverse transcription-polymerase chain reaction in formalin-fixed, paraffin-embedded tumor
    Anna Isphording
    Department of Pathology and Laboratory Medicine, and Genetic Pathology Evaluation Center, Vancouver General Hospital, Vancouver, British Columbia, Canada V5Z 4E3
    Hum Pathol 44:837-43. 2013
    ....
  39. doi request reprint Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer
    Alan I So
    The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:6944-54. 2008
    ..This study assesses the effect of IGFBP-2 on the behavior of human breast cancer using clinical specimens as well as in vitro and in vivo experimental systems...
  40. doi request reprint Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options
    David Voduc
    Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Breast Cancer 8:S171-8. 2008
    ..Particular emphasis is placed on the clinical implications of basal breast cancer and potential therapeutic options available to oncologists...
  41. pmc CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer
    Shuzhen Liu
    Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, 2660 Oak Street, Vancouver, BC, V6H 3Z6, Canada
    Breast Cancer Res 14:R48. 2012
    ..We conducted this study to assess CD8+ (cytotoxic T) lymphocyte infiltration in a large cohort of invasive early stage breast cancers, and to evaluate its prognostic effect in different breast cancer intrinsic subtypes...
  42. pmc A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen
    Stephen K Chia
    Department of Medical Oncology, British Columbia Cancer Agency, British Columbia, Canada
    Clin Cancer Res 18:4465-72. 2012
    ..12) to evaluate the prognostic and predictive significance of intrinsic subtypes identified by both the PAM50 gene set and by immunohistochemistry...
  43. ncbi request reprint Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin
    Torsten O Nielsen
    British Columbia Research Institute for Children s and Women s Health, Department of Pediatrics, Laboratory for Oncogenomic Research, University of British Columbia, Vancouver British Columbia, Canada
    Cancer Res 64:286-91. 2004
    ..Thus, our study raises the possibility that 17AAG could prove to be an effective therapeutic agent for a large number of breast cancer patients by inhibiting the IGF-IR and ultimately uPA...
  44. ncbi request reprint Nuclear beta-catenin in mesenchymal tumors
    Tony L Ng
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Mod Pathol 18:68-74. 2005
    ..High-level nuclear beta-catenin staining serves as a useful diagnostic tool, as it is specific to a small subset of mesenchymal tumors...
  45. doi request reprint Activating transcription factor 2 in mesenchymal tumors
    Makoto Endo
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, British Columbia, Canada Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada Department of Anatomic Pathology, Kyushu University, Fukuoka, Japan Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan
    Hum Pathol 45:276-84. 2014
    ..Cytoplasmic ATF2 expression was less frequently seen than nuclear expression in malignant mesenchymal tumors. Benign mesenchymal tumors mostly showed much lower nuclear and cytoplasmic ATF2 expression. ..
  46. pmc Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology
    Torsten O Nielsen
    Department of Pathology and Genetic Pathology Evaluation Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Am J Pathol 163:1449-56. 2003
    ..Digital images from over 2500 immunostained cores analyzed in this study were captured and are made accessible through the accompanying website: http://microarray-pubs.stanford.edu/tma_portal/synsarc...
  47. pmc Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement
    Cheng Han Lee
    Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, BC, Canada
    Am J Surg Pathol 36:1562-70. 2012
    ..When evaluating high-grade uterine sarcomas, cyclin D1 can be included in the immunohistochemical panel as an indicator of YWHAE-FAM22 ESS...
  48. pmc Tissue microarrays in clinical oncology
    David Voduc
    Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Semin Radiat Oncol 18:89-97. 2008
    ..This review describes the impact of TMA-based research in clinical oncology and its potential future applications. Technical aspects of TMA construction and the advantages and disadvantages inherent to this technology are also discussed...
  49. ncbi request reprint Molecular characterisation of soft tissue tumours: a gene expression study
    Torsten O Nielsen
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
    Lancet 359:1301-7. 2002
    ..We aimed to start molecular characterisation of these rare neoplasms and to do a genome-wide search for new diagnostic markers...
  50. doi request reprint Histone deacetylase 1 and 2 in mesenchymal tumors
    Marina Pacheco
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
    Mod Pathol 25:222-30. 2012
    ....
  51. doi request reprint Low-grade fibromyxoid sarcoma of the perineum with heterotopic ossification: case report and review of the literature
    Anna F Lee
    Department of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, British Columbia V5Z1M9, Canada
    Hum Pathol 42:1804-9. 2011
    ..This case demonstrates the value of having a distinctive confirmatory molecular pathology test for diagnosis and expands our knowledge of the histologic variants possible in low-grade fibromyxoid sarcoma...
  52. pmc An international Ki67 reproducibility study
    Mei Yin C Polley
    Affiliations of authors Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD MCP, LMM Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada SCYL, DG, EM, TON Department of Laboratory Medicine and Pathology, University of Alberta, Alberta, Canada JCH Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy MGM Division of Pathology and Laboratory Medicine, European Institute of Oncology, and University of Milan, Milan, Italy GV Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom LAZ Department of Pathology, Centre Jean Perrin, Clermont Ferrand, and Université d Auvergne, France FP L Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada JMSB PhenoPath Laboratories, Seattle, WA AMG Department of Pathology, MD Anderson Cancer Center, Houston, TX WFS Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom TP The EMMES Corporation, Rockville, Germany
    J Natl Cancer Inst 105:1897-906. 2013
    ..A working group was assembled to devise a strategy to harmonize Ki67 analysis and increase scoring concordance. Toward that goal, we conducted a Ki67 reproducibility study...
  53. doi request reprint Duodenal epithelioid gastrointestinal stromal tumor with prominent granular cell features
    Anna Adamiak
    Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, BC, Canada
    Hum Pathol 40:599-602. 2009
    ..The current case illustrates the importance of considering gastrointestinal stromal tumor in the differential diagnosis of any epithelioid tumors in the gastrointestinal tract or the abdominal-pelvic cavity...
  54. pmc deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data
    Andrew McPherson
    Centre for Translational and Applied Genomics, BC Cancer Agency, Vancouver, British Columbia, Canada
    PLoS Comput Biol 7:e1001138. 2011
    ....
  55. pmc Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans
    Sabine C Linn
    Departments of Pathology, Genetics, and Biochemistry, and Howard Hughes Medical Institute, Stanford University Medical Center, Stanford, California 94305, USA
    Am J Pathol 163:2383-95. 2003
    ....
  56. ncbi request reprint Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone
    Cheng Han Lee
    Department of Pathology, Stanford University, Stanford, CA, USA
    Mod Pathol 21:531-9. 2008
    ..These findings altogether show that p63 can be used as a diagnostic marker to aid the clinical diagnosis of GCTOB...
  57. ncbi request reprint FOXA1 expression in breast cancer--correlation with luminal subtype A and survival
    Sunil Badve
    Department of Pathology, Indiana University School of Medicine, Indianapolis, USA
    Clin Cancer Res 13:4415-21. 2007
    ..It segregates with genes that characterize the luminal subtypes in DNA microarray analyses. The utility of FOXA1 as a possible independent prognostic factor has not been determined in breast cancers...
  58. ncbi request reprint Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma
    Nikita A Makretsov
    Genetic Pathology Evaluation Centre of the Department of Pathology, and Prostate Research Centre of Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Canada
    Clin Cancer Res 10:6143-51. 2004
    ..This work demonstrates that hierarchical clustering of immunostaining data by using multiple markers can group breast cancers into classes with clinical relevance and is superior to the use of individual prognostic markers...
  59. pmc Determination of stromal signatures in breast carcinoma
    Robert B West
    Department of Pathology, Stanford University Medical Center, Stanford, California, USA
    PLoS Biol 3:e187. 2005
    ..Our findings suggest that the host stromal response varies significantly among carcinomas and that gene expression patterns characteristic of soft tissue tumors can be used to discover new markers for normal connective tissue cells...
  60. ncbi request reprint The gene expression profile of extraskeletal myxoid chondrosarcoma
    Subbaya Subramanian
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94035, USA
    J Pathol 206:433-44. 2005
    ..Small molecule inhibitors for PPARG exist and PPARG could be a potential therapeutic target for EMC...
  61. ncbi request reprint Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer
    Brian Z Ring
    Applied Genomics Inc, 863 Mitten Rd 103, Burlingame, CA, USA
    J Clin Oncol 24:3039-47. 2006
    ..We have used gene expression data to guide the production of hundreds of novel antibody reagents to discover novel diagnostic tools for stratifying carcinoma patients...
  62. ncbi request reprint cDNA microarray-based translational research in soft tissue sarcoma
    Joanna M Lubieniecka
    J Surg Oncol 92:267-71. 2005
    ..Recent results in synovial sarcoma are used to highlight the applicability of this technology for marker and target discovery, as well as the need for preclinical validation of putative therapeutic targets...
  63. ncbi request reprint Prognostic significance of macrophage infiltration in leiomyosarcomas
    Cheng Han Lee
    Department of Pathology, Stanford University Medical Center, Stanford, California 94305, USA
    Clin Cancer Res 14:1423-30. 2008
    ..Their presence is associated with poor clinical outcome in a variety of epithelial malignancies. The aim of this study is to examine the prognostic significance of tumor-associated macrophages in sarcomas...
  64. ncbi request reprint Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry
    Forrest D Hsu
    Department of Pathology and Genetic Pathology Evaluation Centre, Vancouver General Hospital and the University of British Columbia, Canada
    Mod Pathol 15:1374-80. 2002
    ....
  65. ncbi request reprint Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway
    Sonja E Steigen
    Department of Pathology, Institute of Medical Biology, University of Tromsø, Norway
    Mod Pathol 21:46-53. 2008
    ..Expression of p16 was significantly correlated with unfavorable prognosis, whereas L1 expression was not...
  66. ncbi request reprint Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides
    John S Cupp
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Am J Surg Pathol 31:970-6. 2007
    ....
  67. doi request reprint A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors
    Inigo Espinosa
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Am J Surg Pathol 32:210-8. 2008
    ..5%) synovial sarcomas among the 935 soft tissue tumors examined showed positive immunostaining for DOG1.1. In addition, DOG1.1 immunoreactivity was seen in fewer cases of carcinoma, melanoma, and seminoma as compared with KIT...
  68. ncbi request reprint Deconstructing the molecular portrait of basal-like breast cancer
    Fruma Yehiely
    Cell Death Regulation Laboratory, Departments of Medicine and Cell and Molecular Biology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Trends Mol Med 12:537-44. 2006
    ..Here, we focus on new insights into the molecular pathogenesis of basal-like breast cancer and explore how these discoveries might impact the treatment of these poor-prognosis tumors...
  69. ncbi request reprint Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
    Grace M Callagy
    Cancer Genomics Program, Department of Oncology, Hutchison Medical Research Council Research Centre, University of Cambridge, United Kingdom
    Clin Cancer Res 12:2468-75. 2006
    ..We validated the results in an independent series...
  70. ncbi request reprint Opportunities for improving the therapeutic ratio for patients with sarcoma
    Jay S Wunder
    University Musculoskeletal Oncology Unit and Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada
    Lancet Oncol 8:513-24. 2007
    ..Research in stem-cell biology and nanotechnology holds promise for additional novel treatment options in the future...
  71. pmc AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer
    Jose V Moyano
    Cell Death Regulation Laboratory, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Clin Invest 116:261-70. 2006
    ..Our data also implicate the MEK/ERK pathway as a potential therapeutic target for these tumors...
  72. ncbi request reprint CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' reply
    Jay S Wunder
    University Musculoskeletal Oncology Unit and Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Lancet Oncol 8:668-9. 2007
  73. ncbi request reprint TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays
    Chih Long Liu
    Biological and Biomedical Sciences Program, Division of Medical Sciences, Harvard Medical School, Cambridge, MA 02138, USA
    Mod Pathol 18:1641-8. 2005
    ..This greatly facilitates analysis of tissue microarrays, particularly for users with large repositories of data, and may facilitate discovery of biological trends and help refine diagnostic accuracy of tissue markers in clinical samples...
  74. ncbi request reprint Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles
    Subbaya Subramanian
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Oncogene 23:7780-90. 2004
    ..These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated...
  75. ncbi request reprint Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans
    Robert B West
    Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Am J Surg Pathol 28:1063-9. 2004
    ..stanford.edu/tma_portal/apod/). We conclude that Apo D is strongly expressed in DFSPs and neural lesions and may be useful in differentiating DFSP from fibrous histiocytoma...
  76. pmc The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status
    Robert B West
    Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Am J Pathol 165:107-13. 2004
    ..Reactivity for DOG1 may aid in the diagnosis of GISTs, including PDGFRA mutants that fail to express KIT antigen, and lead to appropriate treatment with imatinib mesylate, an inhibitor of the KIT tyrosine kinase...
  77. ncbi request reprint Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
    ..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...